vTv Therapeutics (VTVT) Total Liabilities (2014 - 2026)

vTv Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $9.0 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 62.73% year-over-year to $9.0 million; the TTM figure through Jun 2026 stood at $9.0 million (down 62.73% YoY), while the FY2025 annual figure was $25.5 million, up 6.25% from the prior year.
• Total Liabilities came in at $9.0 million for Q2 2026 at vTv Therapeutics, up from $8.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.6 million in Q2 2022 to a low of $8.9 million in Q1 2026.
• Average Total Liabilities over 5 years is $24.3 million, with a median of $26.7 million recorded in 2022.
• Year-over-year, Total Liabilities surged 233.11% in 2022 and plunged 62.73% in 2026.
• Over 5 years, Total Liabilities stood at $27.4 million in 2022, then gained by 7.91% to $29.6 million in 2023, then fell by 18.95% to $24.0 million in 2024, then advanced by 6.25% to $25.5 million in 2025, then tumbled by 64.81% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $9.0 million in Q2 2026, $8.9 million in Q1 2026, and $25.5 million in Q4 2025.